Evidence Hub

C-reactive protein-triglyceride glucose index in evaluating cardiovascular disease and all-cause mortality incidence among individuals across stages 0–3 of cardiovascular–kidney–metabolic syndrome: a nationwide prospective cohort study

Huiwen Ou, Miao-Miao Wei, Xin Li, Xiao-Shuang Xia

Cardiovascular Diabetology, 2025

5,847 participants · 81 citations

Abstract

The American Heart Association (AHA) developed the notion of cardiovascular–kidney–metabolic (CKM) syndrome, which emphasizes the interconnection of heart, kidney, and metabolic illnesses. The C-reactive protein-triglyceride-glucose (CTI) represents a potential indicator to assess the resistance to insulin and an inflammatory response. However, the connection among CTI, cardiovascular disease (CVD) incidence, and overall mortality rates remains uncertain, particularly among individuals at CKM stages 0–3. The China Health and Retirement Longitudinal Study (CHARLS) enrolled 17,705 middle-aged and elderly people. The primary outcome was the occurrence of CVD and overall mortality rates. The CTI was obtained by 0.412 * Ln (CRP [mg/L]) + Ln (TG [mg/dL] × FPG [mg/dL])/2. The correlation among CTI and CVD incidence and overall mortality was assessed via Cox proportional hazard models, Kaplan–Meier curves and restricted cubic spline (RCS) analysis. To improve the study results, a stratified analysis evaluated the influence of varying socio-demographic characteristics. This study involved 5723 participants for CVD and 5847 participants for all-cause mortality in the CKM syndrome stages 0–3. RCS analysis revealed a notable non-linear association between CTI and CVD occurrence, as well as a linear association between CTI and all-cause death. After comprehensive multivariate adjustment, the data showed a striking 111% increase in overall mortality risk for every 1-unit rise in…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 5,847 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free